Jubilant Life Sciences, an integrated global pharmaceuticals and life sciences company, has announced that the company has received final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally disintegrating 5 mg and 10 mg tablets.

The tablets are used for the acute treatment of migraine in adults and in pediatric patients.

Rizatriptan Benzoate tablets are the generic version of Maxalt-MLT orally disintegrating, 5 mg and 10 mg Tablets of Merck.

As on Jun. 30, 2015, the company had a total of 815 filings for formulations of which 389 have been approved in various regions globally.

Shares of the company gained Rs 11.2, or 2.88%, to trade at Rs 399.50. The total volume of shares traded was 279,193 at the BSE (12.29 p.m., Tuesday).